# To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)

> **NCT01257737** · PHASE4 · COMPLETED · sponsor: **Amgen** · enrollment: 88 (actual)

## Conditions studied

- Urea Cycle Disorders

## Interventions

- **DRUG:** HPN-100

## Key facts

- **NCT ID:** NCT01257737
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-04
- **Primary completion:** 2017-02-16
- **Final completion:** 2017-02-16
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2024-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01257737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01257737, "To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT01257737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*